HAE - Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript
2024-05-10 00:25:23 ET
Haemonetics Corporation (HAE)
Q4 2024 Earnings Conference Call
May 09, 2024 08:00 AM ET
Company Participants
Olga Guyette - Senior Director of Investor Relations and Treasury
Christopher Simon - President and Chief Executive Officer
James D'Arecca - Executive Vice President and Chief Financial Officer
Conference Call Participants
Anthony Petrone - Mizuno Group
Larry Solow - CJS Securities
Joanne Wuensch - Citi
Andrew Cooper - Raymond James
Mike Matson - Needham & Company
Michael Petusky - Barrington Research
David Turkaly - Citizens JMP
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Q4 2024 Haemonetics Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Olga Guyette, Senior Director of Investor Relations and Treasury. Olga, please go ahead.
Olga Guyette
Good morning. Thank you for joining us for Haemonetics fourth quarter and fiscal year 2024 conference call and webcast. I'm joined today by Chris Simon, our CEO; who will provide business update and discuss revenue results and guidance and James D'Arecca, our CFO who will provide further updates about our fiscal year 2024 financial performance and expectations for fiscal year 2025.
Before we begin, I'd like to address revenue reporting changes we're implementing, starting with our fiscal year 2025. These changes involve integrating service revenue within our commercial business unit. This adjustment is in line with our updated management structure and acknowledges the crucial role that services play in our customer offerings. It underscores our commitment to improving service quality and driving growth within our service organization.
As a result of this change, the fiscal year 2025 guidance we will discuss today is presented in our new revenue reporting format. All revenue results for the fourth quarter in fiscal year 2024 are presented in the old format to facilitate appropriate year-over-year comparisons. For a detailed reconciliation between the old and the new revenue reporting format, please refer to the supplemental analysis referenced in this morning's earnings release and also available on the IR section of our website.
I'd like to remind everyone that all revenue growth rates discussed today are organic unless specified otherwise and exclude the impact of foreign exchange fluctuations and acquisitions. Our organic revenue growth guidance for fiscal year 2025 incorporates 15 weeks of revenue from OpSens due to the acquisition closing date being in December 2023....
Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript